Lipoatrophy & HIV: Treatment
Overview
News
- FDA Approves Radiesse for Treating Facial Lipoatrophy (December 29, 2006)
From U.S. Food and Drug Administration
- FDA Approves Radiesse Facial Filler for Two New Aesthetic Indications (December 27, 2006)
To read PDF, click here
From BioForm Medical, Inc.
- Health Canada Provides Bio-Alcamid Injections for Facial Wasting; Full Approval Expected Soon (July 29, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Sculptra Costs Four Times More in U.S. Than in Europe (September 24, 2004)
In Washington Blade
- Approval of Sculptra for Treating Facial Lipoatrophy (August 3, 2004)
From U.S. Food and Drug Administration
- Lipoatrophy Treatment Nears Approval in U.S. (March 26, 2004)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- The FDA Has Accepted the Filing for an Injectable Poly-L-Lactic Acid Called "Sculptra" to Treat Facial Lipoatrophy (February 27, 2004)
The facial wasting treatment known outside the United States as New-Fill moves one step closer to U.S. approval.
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
- Aventis Applies for FDA Approval of Lipoatrophy Treatment (February 10, 2004)
The facial wasting treatment known most widely as New-Fill seeks review for possible approval in the United States.
From Advocate.com
Research